Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd..
Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA-approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Clinical case reports - 9(2021), 10 vom: 11. Okt., Seite e04788 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ansari, Amir M [VerfasserIn] |
---|
Links: |
---|
Themen: |
Case Reports |
---|
Anmerkungen: |
Date Revised 21.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1002/ccr3.4788 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332001512 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332001512 | ||
003 | DE-627 | ||
005 | 20231225214715.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ccr3.4788 |2 doi | |
028 | 5 | 2 | |a pubmed24n1106.xml |
035 | |a (DE-627)NLM332001512 | ||
035 | |a (NLM)34659753 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ansari, Amir M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 21.09.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. | ||
520 | |a Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA-approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a intracranial hemorrhage | |
650 | 4 | |a multiple myeloma | |
650 | 4 | |a platelet transfusion refractoriness | |
650 | 4 | |a recombinant activated FVII | |
650 | 4 | |a thrombocytopenia | |
700 | 1 | |a Khorasanchi, Adam |e verfasserin |4 aut | |
700 | 1 | |a Faghihimehr, Armaghan |e verfasserin |4 aut | |
700 | 1 | |a Toor, Amir |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical case reports |d 2013 |g 9(2021), 10 vom: 11. Okt., Seite e04788 |w (DE-627)NLM234405864 |x 2050-0904 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2021 |g number:10 |g day:11 |g month:10 |g pages:e04788 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccr3.4788 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2021 |e 10 |b 11 |c 10 |h e04788 |